Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Etienne Hanslian has a total of 78 co-authors. Here are the top co-authors by number of shared publications:

  • Christian S. Kessler

    Department of Internal Medicine and Nature-based Therapies, Immanuel Hospital Berlin, Berlin, Germany

    8 shared publications
  • Daniela Artemis Koppold

    Institute of Social Medicine, Epidemiology and Health Economics, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany

    6 shared publications
  • Andreas Michalsen

    Institute of Social Medicine, Epidemiology and Health Economics, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany

    5 shared publications
  • Michael Jeitler

    Institute of Social Medicine, Epidemiology and Health Economics, Charité - University Medical Center Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany

    5 shared publications
  • Nico Steckhan

    Evidence-based Digital Diabetology, Department of Medicine III, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

    5 shared publications
  • Andreas Michalsen

    Institute of Social Medicine, Epidemiology and Health Economics, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

    4 shared publications

Latest Publications

  • Open Access

    Should I drink water or wine? Impacts of online nutritional counseling on the alcohol consumption of elderly individuals with mild cognitive impairment

    by Julia-Sophia Scheuermann, Elmar Graessel, Petra Scheerbaum, Etienne Hanslian, Julia Katharina Schiele, Christian S. Kessler, Carolin Donath

    Background: People with mild cognitive impairment (MCI) have an increased health risk when they consume alcohol in comparison with people without cognitive impairment. Excessive alcohol consumption is an established modifiable risk factor that contributes to the risk of developing dementia. Objective: Within a secondary data analysis of a 2 × 2 randomized controlled trial (RCT) – consisting of a computerized cognitive intervention and a nutrition counseling intervention –, we evaluated the impact of a nutritional counseling group (neither focusing solely on alcohol consumption) on alcohol consumption in people with MCI at a 12-months follow-up, identified predictors of changes in alcohol consumption, and determined whether women benefited in the same way as men. Methods: One hundred eighty-nine (189) of 270 trial participants reported consuming alcohol at baseline and started one of the two nutritional counseling programs (ITT sample). Data were collected at a 12-months follow-up and imputed for n = 15 participants. Participants received either whole-food plant-based (WFPB) nutritional group counseling or nutritional group counseling based on the German Nutrition Society’s (DGE) recommendations. Alcohol consumption was quantified with standard drinks (10 g alcohol)/day. Multiple linear regressions were used to identify potential predictors of reduction. P -values were corrected. Results: The sample’s average age was 70.6 years and nearly showed gender parity (52% female). Both interventions led to a significant reduction in alcohol consumption in people with MCI after 12 months (Cohen''''s d = .30 (WFPB); Cohen''''s d = .39 (DGE)). There were no significant differences in the change in consumption level over time between the nutritional counseling groups ( p = .173). Women substantially reduced their alcohol consumption over time only in the DGE nutritional counseling group (Cohen''''s d = .33). In successful alcohol reducers ( n = 84), higher baseline alcohol consumption (β = .670, p < .001), older age (β = .158, p = .035), and stricter adherence in the counseling group (β = .184, p = .017) were significant predictors of a greater reduction ( F (7,76) = 18.539, p = .003). Higher cognitive functioning was a significant negative predictor of reduction (β = -.199, p = .009). Conclusion: In context of the lifestyle intervention of the BrainFit-Nutrition study, nutritional counseling for people with MCI was effective for reducing alcohol intake. Our results suggest focusing on younger people living with MCI as well as higher educated people, especially men, to optimize the potential of modifiable risk factors for dementia. However, gender differences exist. A gender-specific nutritional counseling program is advised in the light of the gender health gap. Trial registration: ISRCTN10560738; registered 11/23/2021.

  • Open Access

    Effects of nutritional counseling on dietary patterns in patients with mild cognitive impairment: insights from the BrainFit-Nutrition study

    by Etienne Hanslian, Melanie Dell’oRo, Julia K. Schiele, Farid I. Kandil, Dzenita Hasanbasic, Cirus Henn, Elmar Graessel, Julia-Sophia Scheuermann, Petra Scheerbaum, Andreas Michalsen, et al.

    Introduction: This study examines the effects of a structured nutritional counseling intervention for individuals with mild cognitive impairment (MCI) via synchronized online courses conducted bi-weekly over six months.Methods: This work presents a secondary analysis of the BrainFit-Nutrition study, which explored the impacts of both 1) dietary counseling interventions (comparing a Whole Food Plant-Based (WFPB) diet with a diet based on the German Nutrition Association guidelines or Deutsche Gesellschaft für Ernährung, DGE) and 2) standardized versus individualized computer-based cognitive training, within a 2x2 factorial randomized controlled trial design for participants with MCI. While the primary outcome of the BrainFit-Nutrition study assessed the impacts of diet and cognitive training on cognitive performance, this secondary data analysis focuses on dietary habits and their changes over time. Dietary behaviors in 261 participants (52.2% female), aged between 60 and 86 years, were monitored using food frequency questionnaires at baseline (t0), post-intervention (t6), and at a 12-months follow-up (t12). Short-term (t6) and long-term (t12) dietary pattern effects were analyzed by comparing consumption frequencies across various food categories between the dietary groups, employing ANCOVAs with baseline values (t0) as covariates for exploratory analysis.Results: Throughout the intervention period, most participants in both groups maintained an omnivorous diet, with minimal shifts towards pescatarian, ovolacto-vegetarian, and vegan diets, especially in the WFPB group, which saw a minor increase in vegan and ovolacto-vegetarian participants by the end of the study. Across both dietary groups, vegetable, fruit, and whole grain consumption remained steady, with no notable intergroup differences. A decrease in meat, fish, and egg consumption was observed in both groups, with a more marked reduction in the WFPB group.Discussion: These findings suggest that while targeted dietary interventions can foster healthier dietary patterns among MCI patients, the type of dietary choices may be less impactful for individuals with MCI than participation in dietary interventions in general. Further prospective research is warranted to clarify the potential benefits of dietary adjustments on cognitive health and to refine dietary guidance tailored to this specific population.


  • Open Access

    Immunophenotyping of Patients With Rheumatoid Arthritis Reveals Difference in CD27 + IgD + Unswitched Memory B Cell Profiles

    by Bérénice Hansen, Raul Da Costa, Dominique Revets, Fanny Hedin, Maria Konstantinou, Eduardo Rosales Jubal, Franck Ngangom, Cédric C. Laczny, Kirsten Roomp, Viacheslav Petrov, et al.

    Objectives: Over the past decades, the prevalence of noncommunicable diseases has surged significantly, including the systemic autoimmune disorder rheumatoid arthritis (RA). Despite extensive research and advancement of RA therapy, effective prevention strategies or cures remain elusive, and the mechanisms underlying RA pathogenesis unclear. It is crucial to gain deeper insights into RA pathophysiology. The objective of this study is to provide a comprehensive immunophenotyping of patients with RA. Methods: We generated and analyzed deep immunophenotyping data from 52 patients with RA and 47 healthy controls (HCs). Whole blood samples were stained with extracellular markers, and intracellular antibodies and analyzed for 32 different cell markers using mass cytometry by time of flight. The acquired data was analyzed by both manual and automatic unsupervised tools and subsequently complemented with anthropometric data and clinical‐laboratory parameters. Results: We observed a significant disparity in immune cell profiles between patients with RA and HC, notably a reduced frequency of CD27 + IgD + unswitched memory B ( m B) cells in patients with RA ( p ‐value < 0.01), with the disease RA being the primary and only significant factor explaining up to 17.9% of the variance of these cells. Conclusion: Our results reveal, for the first time, that a reduced frequency of unswitched m B cells in patients with RA is the only significant abnormality distinguishing patients with RA from HC in a complex immunophenotyping panel of 72 different cell populations. This provides important information to further individualize various interventions and possibly help to design novel therapeutic interventions.

  • Open Access

    Effects of Prolonged Medical Fasting during an Inpatient, Multimodal, Nature-Based Treatment on Pain, Physical Function, and Psychometric Parameters in Patients with Fibromyalgia: An Observational Study

    by Daniela A. Koppold, Farid I. Kandil, Anna Müller, Oliver Güttler, Nico Steckhan, Sara Meiss, Carolin Breinlinger, Esther Nelle, Anika Rajput Khokhar, Michael Jeitler, et al.

    Fibromyalgia syndrome (FMS) is a common chronic pain disorder and often occurs as a concomitant disease in rheumatological diseases. Managing FMS takes a complex approach and often involves various non-pharmacological therapies. Fasting interventions have not been in the focus of research until recently, but preliminary data have shown effects on short- and medium-term pain as well as on physical and psychosomatic outcomes in different chronic pain disorders. This single-arm observational study investigated the effects of prolonged fasting (3–12 days, p < 0.001) by V1, suggesting an improvement in subjective disease impact. Pain (NRS: reduction by 1.1 ± 2.5 in V1, p < 0.001) and quality of life (WHO-5: +4.9 ± 12.3 in V1, p < 0.001) improved, with a sustainable effect across follow-up visits. In contrast, mindfulness (MAAS: +0.3 ± 0.7 in V1, p < 0.001), anxiety (HADS-A: reduction by 2.9 ± 3.5 in V1, p < 0.0001), and depression (HADS-D: reduction by 2.7 ± 3.0 in V1, p < 0.0001) improved during inpatient treatment, without longer-lasting effects thereafter. During the study period, no serious adverse events were reported. The results suggest that patients with FMS can profit from a prolonged therapeutic fasting intervention integrated into a complex multimodal inpatient treatment in terms of quality of life, pain, and disease-specific functional parameters. ClinicalTrials.gov Identifier: NCT03785197.


  • Open Access

    Patients’ perspectives on prescription cannabinoid therapies: a cross-sectional, exploratory, anonymous, one-time web-based survey among German patients

    by Jan Moritz Fischer, Farid I. Kandil, Ekaterina Katsarova, Laura Sophie Zager, Michael Jeitler, Felix Kugler, Franziska Fitzner, Vijayendra Murthy, Etienne Hanslian, Christoph Wendelmuth, et al.

    Introduction: Since cannabinoids were partially legalized as prescription medicines in Germany in 2017, they are mostly used when conventional therapies do not suffice. Ambiguities remain regarding use, benefits and risks. This web-based survey explored the perspectives of patients whose experiences are not well enough known to date.Methods: In an anonymous, exploratory, cross-sectional, one-time web-based observational study, participants receiving cannabinoid therapy on prescription documented aspects of their medical history, diagnoses, attitudes toward cannabinoids, physical symptoms, and emotional states. Participants completed the questionnaires twice here: first regarding the time of the survey and then, retrospectively, for the time before their cannabinoid therapy. Participants were recruited in a stratified manner in three German federal states.Results: N = 216 participants (48.1% female, aged 51.8 ± 14.0) completed the survey, most of which (72%, n = 155) reported pain as their main reason for cannabinoid therapy. When comparing the current state with the retrospectively assessed state, participants reported greater satisfaction with their overall medical therapy (TSQM II: +47.9 ± 36.5, p < 0.001); improved well-being (WHO-5: +7.8 ± 5.9, p < 0.001) and fewer problems in PROMIS subscales (all p < 0.001). Patients suffering primarily from pain (72%, n = 155) reported a reduction of daily pain (NRS: −3.2 ± 2.0, p < 0.001), while participants suffering mainly from spasticity (8%, n = 17) stated decreased muscle spasticity (MSSS: −1.5 ± 0.6, p < 0.001) and better physical mobility (−0.8 ± 0.8, p < 0.001). Data suggests clinically relevant effects for most scores. Participants’ attitudes toward cannabinoids (on a 5-point scale) improved (+1.1 ± 1.1, p < 0.001). Most patients (n = 146, 69%) did not report major difficulties with the cannabinoid prescription process, while (n = 27; 19%) had their cannabinoid therapy changed due to side effects.Discussion: Most participants experienced their therapy with cannabinoids as more effective than their previous therapy. There are extensive limitations to this cross-sectional study: the originally intended representativeness of the dataset was not reached, partly due to the SARS-CoV-2 pandemic; the sample has a larger proportion of privately insured and self-paying patients. Results does not suggest that cannabinoid patients belong to a particular clientele. Effect sizes observed for pain reduction, quality of life, social participation, and other outcomes suggest a therapeutic potential, particularly in the treatment of chronic pain.


  • Open Access

    Protocol for a multicentre cross-sectional, longitudinal ambulatory clinical trial in rheumatoid arthritis and Parkinson’s disease patients analysing the relation between the gut microbiome, fasting and immune status in Germany (ExpoBiome)

    by Bérénice Hansen, Cédric C Laczny, Velma T E Aho, Audrey Frachet-Bour, Janine Habier, Marek Ostaszewski, Andreas Michalsen, Etienne Hanslian, Daniela A Koppold, Anika M Hartmann, et al.

    Introduction Chronic inflammatory diseases like rheumatoid arthritis (RA) and neurodegenerative disorders like Parkinson’s disease (PD) have recently been associated with a decreased diversity in the gut microbiome, emerging as key driver of various diseases. The specific interactions between gut-borne microorganisms and host pathophysiology remain largely unclear. The microbiome can be modulated by interventions comprising nutrition. The aim of our clinical study is to (1) examine effects of prolonged fasting (PF) and time-restricted eating (TRE) on the outcome parameters and the immunophenotypes of RA and PD with (2) special consideration of microbial taxa and molecules associated with changes expected in (1), and (3) identify factors impacting the disease course and treatment by in-depth screening of microorganisms and molecules in personalised HuMiX gut-on-chip models, to identify novel targets for anti-inflammatory therapy. Methods and analysis This trial is an open-label, multicentre, controlled clinical trial consisting of a cross-sectional and a longitudinal study. A total of 180 patients is recruited. For the cross-sectional study, 60 patients with PD, 60 patients with RA and 60 healthy controls are recruited at two different, specialised clinical sites. For the longitudinal part, 30 patients with PD and 30 patients with RA undergo 5–7 days of PF followed by TRE (16:8) for a period of 12 months. One baseline visit takes place before the PF intervention and 10 follow-up visits will follow over a period of 12 months (April 2021 to November 2023). Ethics and dissemination Ethical approval was obtained to plan and conduct the trial from the institutional review board of the Charité-Universitätsmedizin Berlin (EA1/204/19), the ethics committee of the state medical association (Landesärztekammer) of Hessen (2021–2230-zvBO) and the Ethics Review Panel (ERP) of the University of Luxembourg (ERP 21–001 A ExpoBiome). The results of this study will be disseminated through peer-reviewed publications, scientific presentations and social media. Trial registration number NCT04847011.


  • Open Access

    Are Protective Activities and Limitations in Practical Skills of Daily Living Associated with the Cognitive Performance of People with Mild Cognitive Impairment? Baseline Results from the BrainFit-Nutrition Study

    by Petra Scheerbaum, Elmar Graessel, Sophia Boesl, Etienne Hanslian, Christian S. Kessler, Julia-Sophia Scheuermann

    Limitations in daily living have not yet been described adequately for mild cognitive impairment (MCI). In this study, we investigated first, time spent on protective activities (social, mental, and physical) and second, limitations in practical skills of daily living, both for people with MCI. We used baseline data from 270 individuals who participated in the randomized controlled trial BrainFit-Nutrition. The Montreal Cognitive Assessment (MoCA) was used to identify people with MCI. Participants were asked how much time they spent engaged in social, mental, and physical activities each week. Furthermore, the Bayer-ADL scale was used to quantify deficits in activities of daily living (ADLs). Regarding protection, the number of hours spent engaged in the three activity areas was significantly correlated with the cognitive performance in people with MCI. Social activities were positively associated with current cognitive performance. Concerning the limitations in practical skills of daily living, older and more cognitively impaired individuals were affected. Memory and orientation appear to be among the first practical skills of daily living that become impaired in people with MCI. Treatment recommendations for people with MCI include an increase in social, mental, and physical activities as well as the promotion of a healthy lifestyle.


  • Fasten – ein potentes Therapeutikum der Moderne

    by Etienne Hanslian, Daniela Koppold, Andreas Michalsen

    Fasten als Therapie hat im letzten Jahrzehnt durch eine Fülle an Grundlagenstudien und experimentellen Arbeiten sowie zunehmende klinische Forschung seinen Einzug in die moderne Medizin gehalten. Es ist ein Verfahren mit jahrtausendealter Tradition und dadurch verschiedenartigen Durchführungsmöglichkeiten. Gemeinsam ist ihnen die Reduktion der täglichen Nahrungsaufnahme für begrenzte Zeit. Diese hat vielfältige Wirkungen auf Stoffwechsel, Zellen und Organsysteme, die es zu einem potenten Mittel im ärztlichen Handeln machen können. Therapeutic fasting has found its way into modern medicine in the last decade through a multitude of experimental work and animal studies as well as increasing clinical research. It is a procedure with a tradition dating back thousands of years and thus comes with a variety of different practices. What they all have in common, is the reduction of daily food intake for a limited period of time. This has a variety of effects on metabolism, cells and organ systems, which can make it a potent tool in medical practice. Article published online: 04 August 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Open Access

    Effects of Prolonged Fasting during Inpatient Multimodal Treatment on Pain and Functional Parameters in Knee and Hip Osteoarthritis: A Prospective Exploratory Observational Study

    by Daniela A. Koppold, Farid I. Kandil, Oliver Güttler, Anna Müller, Nico Steckhan, Sara Meiß, Carolin Breinlinger, Esther Nelle, Anika M. Hartmann, Michael Jeitler, et al.

    Preliminary clinical data suggest that pain reduction through fasting may be effective for different diagnoses. This uncontrolled observational clinical study examined the effects of prolonged modified fasting on pain and functional parameters in hip and knee osteoarthritis. Patients admitted to the inpatient department of Internal Medicine and Nature-based Therapies of the Immanuel Hospital Berlin between February 2018 and December 2020 answered questionnaires at the beginning and end of inpatient treatment, as well as at 3, 6, and 12 months after discharge. Additionally, selected blood and anthropometric parameters, as well as subjective pain ratings, were routinely assessed during the inpatient stay. Fasting was the only common intervention for all patients, being performed as part of a multimodal integrative treatment program, with a daily caloric intake of p < 0.001; d = 0.78) and pain alleviation (NRS Pain: −2.7 ± 1.98, p < 0.001, d = 1.48). Pain medication was reduced, stopped, or replaced by herbal remedies in 36% of patients. Improvements were also observed in secondary outcome parameters, including increased quality of life (WHO-5: +4.5 ± 4.94, p < 0.001, d = 0.94), reduced anxiety (HADS-A: −2.1 ± 2.91, p < 0001, d = 0.55) and depression (HADS-D: −2.3 ± 3.01, p < 0.001, d = 0.65), and decreases in body weight (−3.6 kg ± 1.65, p < 0.001, d = 0.21) and blood pressure (systolic: −6.2 ± 15.93, p < 0.001, d = 0.43; diastolic: −3.7 ± 10.55, p < 0.001, d = 0.43). The results suggest that patients with osteoarthritis of the lower extremities may benefit from prolonged fasting as part of a multimodal integrative treatment to improve quality of life, pain, and disease-specific functional parameters. Confirmatory randomized controlled trials are warranted to further investigate these hypotheses.


  • Open Access

    Effects of Prolonged Fasting During Inpatient Multimodal Treatment on Pain and Functional Parameters in Knee and Hip Osteoarthritis: A Prospective Exploratory Observational Study

    by Daniela Artemis Koppold, Farid I. Kandil, Oliver Güttler, Anna Müller, Nico Steckhan, Sara Meiß, Carolin Breinlinger, Esther Nelle, Anika M. Hartmann, Michael Jeitler, et al.

    Preliminary clinical data suggest pain reduction through fasting in different diagnoses. This uncontrolled observational clinical study examined the effects of prolonged modified fasting on pain and functional parameters in hip and knee osteoarthritis. Patients admitted to the inpatient department of Internal Medicine and Nature-based Therapies of the Immanuel Hospital Berlin between February 2018 and March 2020, answered questionnaires at the beginning and end of inpatient treatment, as well as 3, 6 and 12 months after discharge. Additionally, selected blood and anthropometric parameters were routinely assessed during the inpatient stay. Fasting was performed as part of a multimodal integrative treatment program, with daily caloric intake of <600 kcal for 7.7 ± 1.7 days. N=125 consecutive patients were included. Results revealed an amelioration of overall symptomatology (WOMAC Index score: -14.8±13.31; p<0.001; d=0.78), and pain alleviation (NRS Pain: -2.7±1.98, p<0.001, d=1.48). Pain medication was reduced, stopped, or replaced by herbal remedies in 36% of patients. Improvements were also observed in secondary outcome parameters, including increased quality of life (WHO-5: +4.5±4.94, p<0.001, d=0.94), reduced anxiety (HADS-A: -2.1±2.91, p<0001, d=0.55) and depression (HADS-D: -2.3±3.01, p<0.001, d=0.65), decreases in body weight (-3.6 kg ± 1.65, p< 0.001, d=0.21), and blood pressure (systolic: -6.2±15.93, p<0.001, d= 0.43; diastolic: -3.7±10.55, p<0.001, d=0.43). Results suggest that patients with osteoarthritis of the lower extremities may profit from a prolonged fast embedded in a multimodal integrative treatment regarding quality of life, pain, and disease-specific functional parameters. Confirmatory RCTs are warranted to further investigate these hypotheses.